74. Tsukamoto T, Igarashi H, Chaganti RS, et al. Poor prognosis in multiple myeloma is associated with both partial or complete deletion of chromosome 13 or abnormalities involving 1q and not with other karyotype abnormalities. Blood 1995;86:4350–4356.


178. Roodman GD. Mechanics of bone lesions in multiple myeloma and lymphe- 

179. Bataille R, Manolagas SC, Benonoff JR. Pathogenesis and management of bone 


182. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and 
CCR5 to induce osteoclast formation and increase adhesion of myeloma cells 

183. Tricot G. New Insights into role of microenvironment in multiple myeloma. 

184. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that 

secreted protein involved in the regulation of bone density [see comments]. 

DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl 

187. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a 

myeloma cell survival, and osteoclastogenesis and is a promising target for 

189. Broder S, Humphrey R, Durie M, et al. Impaired synthesis of polyclonal (non-
paraprotein) immunoglobulins by circulating lymphocytes from patients with 

190. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple 

191. Cook G, Campbell JD, Carr CE, et al. Transforming growth factor beta from 
multiple myeloma cells induces osteoclastogenesis and is a promising target for 

192. Perico N, Fadini GP, Salvetti A, et al. Analysis of the efficacy and tox-
icity of bortezomib for treatment of relapsed or refractory multiple myeloma. 

193. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and 
CCR5 to induce osteoclast formation and increase adhesion of myeloma cells 

194. Perico N, Fadini GP, Salvetti A, et al. Analysis of the efficacy and tox-
icity of bortezomib for treatment of relapsed or refractory multiple myeloma. 


196. Miralles GD, O’Fallon JR, Talley NJ. Plasma-cell dyscrasia with poly-

patients with asymptomatic multiple myeloma. Report on 10 patients and a review of the literature. 


384. Morgan GM, Davies FE, Gregory WM, et al. First-line treatment with zole-


386. Kelle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncol-

387. Lee CK, Krop IE, Busque L, et al. DTTMAC: an effective, novel combi-

388. Jagannath S, Vui R, Stewart AK, et al. Allogeneic bone marrow trans-


